NASDAQ · KZIA
Kazia Therapeutics Ltd ADR
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
Loading market information…
NASDAQ · QLGN · USD
Stock price, earnings
Quote as of Nov 18, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Qualigen Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Qualigen Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$0.44-$0.01 (-3.16%)
Ensysce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.36% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$2.12+$0.02 (+0.95%)
Xenetic Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.09% below the high.
$0.18-$0.00 (-2.67%)
KALA BIO, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
$2.34-$0.30 (-11.36%)
Titan Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.55% below the high.
$5.85-$0.21 (-3.47%)
Clearmind Medicine Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
